Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Zongertinib Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PHAR.750

    Clinical Policy: Zongertinib (Hernexeos)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.750 alerts

    Get alerted when Policy CP.PHAR.750 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity and prior-authorization coverage for zongertinib (Hernexeos), primarily for adults with unresectable, recurrent, advanced, or metastatic nonsquamous non-small cell lung cancer with activating HER2 (ERBB2) mutations.

    Policy Summary
    PayerAmbetter Nevada
    PolicyZongertinib (Hernexeos) Coverage
    Policy CodePolicy CP.PHAR.750
    Change TypeMaterial clinical criteria update
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing the member meets all applicable initial approval criteria, including diagnosis, oncology prescriber involvement, age, single-agent use, activating HER2 mutation, and dosing requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The prior systemic therapy requirement was removed from the FDA-approved indication and initial approval criteria to reflect the expanded indication in the prescribing information.

    The ICHRA line of business was added during the 4Q 2026 annual review.

    18+Minimum age
    HER2 (ERBB2)Required mutation
    120 mg/dayMaximum dose under 90 kg
    180 mg/day

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum dose at least 90 kg
    12 monthsApproval duration
    60 mgProduct strength

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met. Approval duration: 12 months.

    ALL of the following

    • Diagnosis of unresectable, recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC).
    • Prescribed by or in consultation with an oncologist.
    • Member is age 18 years or older.>= 18 years
    • Prescribed as a single agent.
    • Disease has activating HER2 (ERBB2) mutations.
    • For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced.
    • ONE of the following

      • Dose does not exceed ONE of the following

        • For body weight less than 90 kg, dose does not exceed 120 mg (2 tablets) per day.< 90 kg: <= 120 mg/day
        • For body weight 90 kg or greater, dose does not exceed 180 mg (3 tablets) per day.>= 90 kg: <= 180 mg/day
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use; prescriber must submit supporting evidence.
    • Prescribed regimen must be FDA-approved or recommended by NCCN.

    Continuation Therapy

    Covered when ALL of the following are met. Approval duration: 12 months.

    ALL of the following

    • Member is currently receiving the medication through the Centene benefit, or documentation supports that the member is currently receiving Hernexeos for a covered indication and has received the medication for at least 30 days.
    • Member is responding positively to therapy.
    • For Hernexeos requests, member must use zongertinib, if available, unless contraindicated or clinically significant adverse effects are experienced.
    • If the request is for a dose increase, ONE of the following must apply

      • New dose does not exceed ONE of the following

        • For body weight less than 90 kg, new dose does not exceed 120 mg (2 tablets) per day.

    Other Diagnoses and Indications

    Other diagnoses or indications are covered only when ONE of the following pathways applies.

    ONE of the following

    • Recent label change pathway

      • The drug has undergone a label change within the last 6 months (for example, a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy.
      • Refer to ONE of the following policies based on formulary or PDL status

        • If the drug is on the formulary (commercial or health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no coverage criteria policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • If the drug is not on the formulary (commercial or health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the applicable line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety under the applicable off-label use policy—CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid—or under the applicable evidence of coverage documents.

    Dose and Duration Parameters

    Body weight under 90 kg
    Weight thresholdBody weight under 90 kg
    Daily dose120 mg per day
    Tablet quantity2 tablets per day
    Body weight at least 90 kg
    Weight thresholdBody weight at least 90 kg
    Daily dose180 mg per day
    Tablet quantity3 tablets per day

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required. Submit documentation establishing that all applicable initial approval criteria are met before coverage can be approved for Hernexeos.

    • Diagnosis of unresectable, recurrent, advanced, or metastatic NSCLC.
    • Prescribed by or in consultation with an oncologist.
    • Member is age ≥ 18 years and Hernexeos is prescribed as a single agent.
    • Disease has activating HER2 (ERBB2) mutations.
    • The prescribed regimen is FDA-approved or recommended by NCCN, or qualifying supporting evidence is submitted for relevant off-label dosing.
    Prior Authorization

    Continuation Prior Authorization

    Continuation prior authorization requires evidence of ongoing covered therapy and benefit. Submit documentation that the member is currently receiving Hernexeos through the Centene benefit, or has received it for at least 30 days for a covered indication, and is responding positively.

    Clinical Background

    Zongertinib (Hernexeos) is a kinase inhibitor indicated for adults with unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) tyrosine kinase domain mutations detected by an FDA-approved test. The indication received accelerated approval based on objective response rate and duration of response; continued approval may depend on confirmation of clinical benefit.

    Definitions and Abbreviations

    Activating HER2 (ERBB2) mutation
    AlterationActivating mutation in the HER2 (ERBB2) tyrosine kinase domain
    Tumor findingA tumor alteration involving an activating HER2 (ERBB2) mutation
    Testing requirementMust be identified by an FDA-approved test
    FDA
    AbbreviationFDA
    DefinitionFood and Drug Administration
    Policy useThe HER2 (ERBB2) mutation must be detected by an FDA-approved test

    Initial NSCLC Therapy

    Initial NSCLC Therapy

    Initial therapy is covered for NSCLC when all listed criteria are met.

    Initial NSCLC therapy

    • Disease and prescriber criteria

      • Diagnosis of unresectable, recurrent, advanced, or metastatic NSCLC.
      • The drug is prescribed by or in consultation with an oncologist.
      • Member is at least 18 years old.≥ 18 years
      • The drug is prescribed as a single agent.

    Continued NSCLC Therapy

    Continued NSCLC Therapy

    Continued therapy is covered when all criteria are met.

    Continued NSCLC therapy

    • Current covered treatment

      • The member is currently receiving the medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Hernexeos for a covered indication and has received it for at least 30 days.≥ 30 days
    • The member is responding positively to therapy.
    • For Hernexeos requests, the member uses zongertinib when available, unless zongertinib is contraindicated or clinically significant adverse effects are experienced.

    Preferred Product Requirement

    StepRequirementExceptions
    1For Hernexeos requests, use zongertinib when available.Zongertinib does not have to be used if it is contraindicated or the member experiences clinically significant adverse effects.

    Zongertinib Quantity Limits

    Zongertinib (Hernexeos)
    Under 90 kg120 mg (2 tablets) per day
    At least 90 kg180 mg (3 tablets) per day
    MedicationZongertinib (Hernexeos)
    Zongertinib (Hernexeos)
    Overall maximum180 mg/day
    MedicationZongertinib (Hernexeos)
    Administration frequencyPer day
    Policy Summary
    PayerAmbetter Nevada
    PolicyZongertinib (Hernexeos) Coverage
    Policy CodePolicy CP.PHAR.750
    Change TypeMaterial clinical criteria update
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing the member meets all applicable initial approval criteria, including diagnosis, oncology prescriber involvement, age, single-agent use, activating HER2 mutation, and dosing requirements.
    SourceLink
    On This Page
    Coverage CriteriaDose and Duration ParametersAuthorization and Documentation RequirementsClinical BackgroundDefinitions and AbbreviationsInitial NSCLC TherapyContinued NSCLC TherapyPreferred Product RequirementZongertinib Quantity Limits
    < 90 kg: <= 120 mg/day
  1. For body weight 90 kg or greater, new dose does not exceed 180 mg (3 tablets) per day.>= 90 kg: <= 180 mg/day
  2. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use; prescriber must submit supporting evidence.
  3. Prescribed regimen must be FDA-approved or recommended by NCCN.
  4. Off-label use pathway

    • The requested use, such as diagnosis, age, or dosing regimen, is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized).
    • The recent label change pathway does not apply.
    • Refer to the off-label use policy for the applicable line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  5. Overall maximum dose
    Maximum daily dose180 mg/day
    Applies toNSCLC dosing
    Administration frequencyPer day
    Minimum therapy duration for continuation
    Minimum durationAt least 30 days
    Applies toContinuation therapy
    DocumentationEvidence that the member is currently receiving covered therapy for at least 30 days
    • If requesting a dose increase, the new dose must meet the applicable weight-based limit or be supported by practice guidelines or peer-reviewed literature for the relevant off-label use.
    • Prescriber must submit supporting evidence for relevant off-label dosing.
    • Approval duration is 12 months.
    Step Therapy

    Zongertinib Product Preference

    Use zongertinib when available. For Hernexeos requests, the member must use zongertinib unless it is contraindicated or clinically significant adverse effects are experienced.

    • This requirement applies to both initial and continued therapy.
    Documentation Required

    Clinical Documentation Required

    Submit clinical documentation supporting that the member meets all approval criteria. Acceptable documentation may include office chart notes, laboratory results, and other relevant clinical information.

    • Include current clinical status, treatment history, prescribed regimen, and relevant response or safety information.
    • Documentation must support the requested initial or continuation authorization, as applicable.
    Documentation Required

    Diagnosis and Biomarker Support

    Documentation must support the covered diagnosis and treatment details, including disease status and the required activating HER2 (ERBB2) mutation.

    • Unresectable, recurrent, advanced, or metastatic nonsquamous NSCLC.
    • Activating HER2 (ERBB2) tyrosine kinase domain mutation detected by an FDA-approved test.
    • For the FDA-approved indication, the member must be an adult with unresectable or metastatic nonsquamous NSCLC.
    • Prescribed by or in consultation with an oncologist and used as a single agent.
    Documentation Required

    Evidence Required for Off-Label Dosing

    When the requested regimen is not within the applicable labeled dosing limits, the prescriber must submit supporting practice guidelines or peer-reviewed literature for the relevant off-label use. The prescribed regimen must be FDA-approved or recommended by NCCN.

    • Supporting evidence is required for relevant off-label dosing during initial therapy or a continuation dose increase.

    Unsupported block type: denial_risk

    Denial Risk

    Dose Exceeds Applicable Limit

    A prescribed dose exceeding the applicable weight-based limit may be denied unless supporting practice guidelines or peer-reviewed literature is submitted for the relevant off-label use.

    • For body weight < 90 kg: maximum 120 mg (2 tablets) per day.
    • For body weight ≥ 90 kg: maximum 180 mg (3 tablets) per day.
    • For a continuation request, the same limits apply to a new dose increase.
    Denial Risk

    Initial Criteria Not Met

    Initial approval may be denied when any required criterion is not met or adequately documented.

    • Disease is not unresectable, recurrent, advanced, or metastatic NSCLC.
    • The prescriber is not an oncologist and there is no oncology consultation.
    • Member is younger than 18 years.
    • Hernexeos is not prescribed as a single agent.
    • An activating HER2 (ERBB2) mutation is not documented.
    • The zongertinib product preference is not followed and no contraindication or clinically significant adverse effect is documented.
    • The regimen exceeds the applicable dose limit without supporting evidence, or is not FDA-approved or recommended by NCCN.
    NSCLC
    AbbreviationNSCLC
    DefinitionNon-small cell lung cancer
    Policy useThe covered indication involves unresectable or metastatic nonsquamous NSCLC
    NCCN
    AbbreviationNCCN
    DefinitionNational Comprehensive Cancer Network
    Policy useThe prescribed regimen must be FDA-approved or recommended by NCCN
  6. The disease has activating HER2 (ERBB2) mutations.
  7. Product requirement

    • For Hernexeos requests, the member uses zongertinib when available, unless zongertinib is contraindicated or clinically significant adverse effects are experienced.
  8. Dosing support

    • Applicable dose limit

      • Body weight is under 90 kg and the dose does not exceed 120 mg (2 tablets) per day.< 90 kg; ≤ 120 mg/day
      • Body weight is at least 90 kg and the dose does not exceed 180 mg (3 tablets) per day.≥ 90 kg; ≤ 180 mg/day
    • The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

      The prescriber must submit supporting evidence.

  9. If the request is for a dose increase, meet ONE of the following

    • Applicable new-dose limit

      • Body weight is under 90 kg and the new dose does not exceed 120 mg (2 tablets) per day.< 90 kg; ≤ 120 mg/day
      • Body weight is at least 90 kg and the new dose does not exceed 180 mg (3 tablets) per day.≥ 90 kg; ≤ 180 mg/day
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use.

      The prescriber must submit supporting evidence.